Effect of different anti-platelet strategies on the long-term outcome after sirolimus drug-eluting stent implantation(EASTS study)

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR-TRC-10001056

Enrollment

Unknown

Registered

2010-10-05

Start date

2011-03-01

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

coronary artery disease

Interventions

1:placebo 75mg qd 12 months

2:clopidogrel 75mg qd 12 months

3:clopidogrel 50mg 1 month, then 25mg 1 month, placebo 75mg qd 10 months

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Age of 18 years of older; 2. The latest PCI with DES implantation before 12 months (stents must be one or more sirolimus-eluting stents); 3. Angiographically confirmed major epicardial vessels (3 2.5mm in diameter) without significant stenosis or restenosis (>50%); 4. Geographically accessible and willing to come in for required study visits; 5. Signed informed consent.

Exclusion criteria

Exclusion criteria: 1. Life expectancy less than 1 years; 2. The patients with hypertensivity or contraindication to aspirin and clopidogrel; 3. Suspected pregnancy; 4. Significant stenosis or restenosis (>50%), or need to be PCI or CABG; 5. EF<35% within 12 months. Or severe congestive heart failure (class III or IV according to NYHA, or pulmonary edema) at the time of enrollment and within 12 months; 6. Severe cardiac valves disease or other severe system diseases; 7. Planned surgical procedure; 8. Complied with idiopathic cardiomyopathy such as dialated cardiomyopathy, hypotrophic cardiomyopathy; 9. Previous stroke or transient ischemia attack within 12 months; 10. Previous myocardial infarction and clinical-driven target vessel revascularization within 12 months; 11. Bleeding events within 12 months; 12. Previous other type DES implantation or BMS implantation history; 13. Extra-cardiac stent implantation history; 14. Current or planned dialysis; 15. Current enrollment in another clinical trial (within 30 days); 16. The patient has a known hypertensivity or contraindication to statins; 17. Current or planned high dose and long-term glucocorticoid treatment.

Design outcomes

Primary

Measure	Time frame
all cause mortality, nonfatal myocardial infarction, or clinical-drivenTVR;	—

Secondary

Measure	Time frame
death, myocardial infarction, any repeat revascularization, strokes, stent thrombosis, cardiac re-h;	—

Countries

China

Contacts

Public ContactGuosheng Fu

fugs@medmail.com.cn+86 13605800707

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026